443 reports of this reaction
3.2% of all FONDAPARINUX SODIUM reports
#3 most reported adverse reaction
PULMONARY EMBOLISM is the #3 most commonly reported adverse reaction for FONDAPARINUX SODIUM, manufactured by Mylan Institutional LLC. There are 443 FDA adverse event reports linking FONDAPARINUX SODIUM to PULMONARY EMBOLISM. This represents approximately 3.2% of all 13,905 adverse event reports for this drug.
Patients taking FONDAPARINUX SODIUM who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is moderately reported among FONDAPARINUX SODIUM users, representing a notable but not dominant share of adverse events.
In addition to pulmonary embolism, the following adverse reactions have been reported for FONDAPARINUX SODIUM:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 443 FDA reports for FONDAPARINUX SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 3.2% of all adverse event reports for FONDAPARINUX SODIUM, making it one of the most commonly reported side effect.
If you experience pulmonary embolism while taking FONDAPARINUX SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.